难治性慢性丙型肝炎患者血浆维生素D水平变化

doi:10.3969/j.issn.1672-5069.2017.02.024

Abstract

Fan Xiaohong， Gao Hong， Jia Nina， et al.. Serum vitamin D levels and its correlation to anti-viral therapy response in difficult-to-treat patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 223-225.

References

[1] Mohd Hanafiah K，Groeger J，Flaxman AD，et al. Global epidemiology of hepatitis C virus infection：new estimates of age-specific antibody to HCV seroprevalence. Hepatology，2013，57（4）:1333-1342.
[2] 中华医学会肝病学分会. 丙型肝炎防治指南. 中华肝脏病杂志，2004，12（4）:194-198.
[3] Petta S，Cammà C，Scazzone C，et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology，2010，51（4）:1158-1167.
[4] Amanzada A，Goralczyk AD，Moriconi F，et al. Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection. J Med Virol，2013，85（9）:1534-1541.
[5] Nagpal S，Na S，Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev，2005，26（5）:662-687.
[6] Schaalan MF，Mohamed WA，Amin HH. Vitamin D deficiency:correlation to interleukin-17，interleukin-23 and PIIINP in hepatitis C virus genotype 4. World J Gastroenterol，2012，18 （28）:3738-3744．
[7] EI Husseiny NM，Fahmy HM，Mohamed WA，et al． Relationship between vitamin D and IL-23，IL-17 and macrophage chemoattractant protein-1 as markers of fibrosis in hepatitis C virus Egyptians. World J Hepatol，2012，4（8）:242-247．
[8] Harrison SA，Rossaro L，Hu KQ，et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. J Hepatol，2010，52（3）:864-874．
[9] Cholongitas E，Theocharidou E，Goulis J，et al． Review article: the extra－skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther，2012，35（6）:634-646．
[10] Lange CM，Bojunga J，Ramos-Lopez E，et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol，2011，54（5）:887-893.
[11] Bitetto D，Fattovich G，Fabris C，et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology，2011，53（4）:1118-1126.
[12] Lemire JM，Archer DC，Beck L，et al. Immunosuppressive actions of 1，25-dihydroxyvitamin D3:preferential inhibition of Th1 functions. J Nutr，1995，125（6 Suppl）:1704S-1708S.
[13] Almerighi C，Bergamini A，Lionetti R，et al. Vitamin D3 modulates T lymphocyte responses in hepatitis C virus-infected liver transplant recipients. Dig Liver Dis，2012，44（1）:67-73.
[14] Sochorová K，Budinsk V，Rozková D，et al. Paricalcitol （19-nor-1，25-dihydroxyvitamin D2） and calcitriol （1，25-dihydroxyvitamin D3） exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol，2009，133（1）:69-77.
[15] Fujimoto T，Tomimatsu M，Iga D，et al. Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. J Gastroenterol Hepatol，2008，23（8 Pt 2）:e432-437.
[16] Kurosaki M，Sakamoto N，Iwasaki M，et al. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol，2011，46（3）:401-409.

Serum vitamin D levels and its correlation to anti-viral therapy response in difficult-to-treat patients with chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[4]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[5]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[6]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[7]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[8]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[9]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[10]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[11]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[12]	Xu Xi, Dang Yinli, Wu Shuo.. Construction and expression of recombinant eukaryotic expression vector of HCV infection related interferon λ4 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 833-836.
[13]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[14]	Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.
[15]	Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.